(Q33344326)

English

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Winnie Yeo

9

0 references

Benny Chung-Ying Zee

object named as

Benny Zee

3

0 references

1 reference

ORCID Public Data File 2021

author name string

Tony S K Mok

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Herman Wong

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kwok Hung Yu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas W T Leung

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tak Wai Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anthony Yim

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anthony T C Chan

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Karen Chak

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Philip Johnson

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1511-1519

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

21 January 2018

Topotecan today

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

The significance of the sequence of administration of topotecan and etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioavailability of low-dose oral etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10836

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10836

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33344326&oldid=2050202176"